Two Israeli Biomed Firms Nab FDA Approval For Separate COVID-19 Trials In US
Both RedHill BioPharma and Pluristem Therapeutics said they were given the green light for their imminent studies treating serious SARS CoV2 infections.
May 10, 2020
European Investment Bank To Provide Israel’s Pluristem With $54M For COVID-19, Other Cell Therapies
Pluristem's PLX cell therapy is being used to treat coronavirus patients with severe complications.
April 30, 2020